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Purpose: The frequencies of apolipoprotein E (APOE) alleles and genotypes were examined in 230 Saudi subjects
including primary open-angle glaucoma (POAG; n=60) and primary angle-closure glaucoma (PACG; n=40) patients as
well as 130 control subjects.
Methods: The presence of glaucoma in patients was based on clinical examination and/or ophthalmic records. The APOE
allele frequency (ε2, ε3, and ε4) was studied by polymerase chain reaction (PCR) followed by reverse-hybridization and
restriction fragment length polymorphism techniques.
Results: Analysis of data showed a complete absence of ε2 allele and a significantly lower frequency of the ε3 allele in
primary glaucoma patients (90.5%) compared to the control subjects (95.7%, p=0.034, relative risk [RR]=0.473, protective
fraction [PF]=0.318). The frequency of the ε4 allele was significantly higher in the glaucoma patients (9.5%) compared
to the control subjects (4.2%, p=0.034, RR=2.169, etiological fraction [EF]=0.329). The ε3/ε3 genotype was more common
in controls than patients (p=0.060, RR=0.465, PF=0.322). The difference in genotype (ε3/ε4) was not statistically
significant between the two groups (p=0.283). Genotype ε4/ε4 was found only in 3% of patients while being completely
absent in the controls (p=0.080). The genotypes, ε2/ε2, ε2/ε3, and ε2/ε4, were absent in both the test and control groups.
When patients were divided on the basis of types of glaucoma, POAG patients had a significantly higher frequency of
ε4 allele and ε4/ε4 genotype than controls whereas there was no significant difference between PACG patient and control
groups in frequencies of APOE alleles and genotypes.
Conclusions: This study indicates that the ε4 allele may be associated with POAG and could be a risk factor while ε3
may be protective for POAG, and APOE polymorphisms may not be associated at all with PACG in Saudis.
Primary glaucoma (PG) is one of the most common eye
diseases that may potentially result in bilateral blindness. It
has been estimated that nearly 66.8 million people worldwide
(around 2%) are affected by glaucoma [1,2]. The disease is
characterized by optic nerve atrophy with an excavated optic
nerve head and progressive visual field loss. The loss of retinal
ganglion cells is the typical pathology in glaucoma [3,4].
Although  elevation  of  intraocular  pressure  (IOP)  is  often
related to the optic nerve damage in glaucoma [5], factors
other than IOP are likely to have a role in the pathogenesis of
glaucomatous optic neuropathy, particularly in individuals
with  normal  tension  glaucoma  (NTG).  Evidence  from
population and family studies supports heredity of glaucoma
to be a complex trait. It is a genetically heterogeneous disorder
attributed to the effects of individual causative mutations as
well  as  interactions  of  multiple  genes  with  a  variety  of
environmental factors [6].
Apolipoprotein E (APOE) is the major apolipoprotein in
the central nervous system, which plays an important role in
the uptake and redistribution of cholesterol within neuronal
network  [7].  APOE  is  synthesized  by  Müller  cells  (the
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predominant  glial  cells  of  the  retina),  released  into  the
vitreous, and then transported into the optic nerve through
anterograde rapid transport where it has an important role in
axonal nutrition [8]. It has been suggested that APOE plays a
role  in  neuronal  survival  following  ischemia  and  other
chemical insults and that a particular APOE isoform may be
related to neuronal degeneration in glaucoma [9]. The gene
encoding APOE has three polymorphic variants in humans,
these variants are designated as ε2, ε3, and ε4. These variants
differ from one another by the presence of either a C or T
nucleotide at codons 112 and 158. These three alleles encode
different  APOE  isoforms,  which  vary  significantly  in
structure and function including receptor binding capacity and
lipid metabolism [10]. As each individual human being carries
two allelic copies in a gene, six possible genotypes (ε2/ε2, ε3/
ε3, ε2/ε3, ε3/ε4, ε2/ε4, and ε4/ε4) are formed by different
combinations of these three alleles. The frequency of these
genotypes differ significantly among different ethnic groups.
However, APOE ε3/ε3 is the most predominant genotype and
e3 the most common allele in majority of populations [11,
12].
Earlier studies clearly point toward a possible association
between APOE alleles and glaucoma. However, the results of
these  studies  are  contradictory.  Some  investigators  show
positive association [9,13,14] while others show no link at all
[15-17]. More over, earlier studies were mainly restricted to
White populations from Australia [9], United Kingdom [15,
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91216], and Sweden [17] with only few reports from other ethnic
groups [13,14]. So far, no attempt has been made to study a
possible association between APOE alleles and glaucoma in
a Saudi population.
METHODS
Subjects: The present study was undertaken to evaluate the
association of APOE alleles and genotype with glaucoma in
Saudi primary glaucoma patients. A total of 100 unrelated
Saudi patients with primary glaucoma (primary open-angle
glaucoma  [POAG]  and  primary  angle-closure  glaucoma
[PACG]) were recruited from the Ophthalmology Clinic of
the Riyadh Military Hospital (Riyadh, Saudi Arabia). The
patient group consisted of 47 males and 53 females with the
age at diagnosis ranging from 30 to 78 years (mean±SD:
58±14.4 years). The control group consisted of 130 unrelated
subjects with 102 males and 28 females and their ages ranging
from 20 to 58 years (mean±SD: 45±11.6 years). The diagnosis
of PG was based on clinical observations.
A  comprehensive  eye  examination  was  done  that
included best-corrected visual acuity (BCVA) measurements
using  the  logarithm  of  the  minimum  angle  of  resolution
(logMAR) 4-m charts (Light House Low Vision Products,
New York, NY), applanation tonometry, gonioscopy, dilated
fundus examination, optic disc photography, and visual field
(VF) examination. On gonioscopy, an angle was considered
occludable if the pigmented trabecular meshwork was not
visible at an angle greater than 180° in dim illumination. Laser
iridotomy was performed in subjects with occludable angles
after  consent  was  obtained.  The  ocular  biometric
measurements were carried out on the following day.
Visual fields: Automated VFs were performed for all subjects
with a BCVA of 4/16 (logMAR 0.6) or better using frequency-
doubling perimetry (Carl Zeiss Meditec Inc., Dublin, CA). All
eligible subjects underwent C-20-1 screening (if the results
were unreliable or abnormal, the test was repeated) and the
N-30 threshold test. The reliability criteria were no fixation or
false-positive errors for the C-20-1 screening test and less than
20% fixation errors and less than 33% false-positive and false-
negative errors for the threshold N-30 test. Visual fields with
no depressed points to any level of sensitivity were considered
to be normal. A provisional diagnosis of suspected glaucoma
was made when the subject had one or more of the following
conditions: intraocular pressure (IOP) ≥21 mmHg in either
eye, vertical cup-to-disc ratio (VCDR) ≥0.7 in either eye or
cup-to disc ratio (CDR) asymmetry ≥0.2, and focal thinning,
notching, or a splinter hemorrhage. All these subjects were
asked  to  perform  a  threshold  VF  test  using  the  Swedish
interactive  threshold  algorithm  Standard  30-2  program
(model 750, Carl Zeiss Meditec Inc.). A glaucomatous field
defect was diagnosed using a single reliable threshold VF
examination of the central 30° (Swedish interactive threshold
algorithm Standard 30-2). The field was considered to be
abnormal if the Glaucoma Hemifield test results were outside
normal limits and if three or more abnormal contiguous non-
edge  points  (except  the  nasal  horizontal  meridian)  were
depressed  to  p<0.05  [18].  Reliability  criteria  were  as
recommended by the instrument’s algorithm (fixation losses
<20%; false-positive and false-negative <33%).
Diagnostic definitions: The distribution of VCDR and IOP
was obtained from those subjects with reliable and normal
supra-threshold  VF  testing  using  frequency-doubling
perimetry.  Cases  of  glaucoma  were  defined  using  the
International  Society  of  Geographical  and  Epidemiologic
Ophthalmology classification [19]. Glaucoma was classified
according to three levels of evidence. In category 1, diagnosis
was based on structural and functional evidence. Using the
Swedish interactive threshold algorithm 30-2, it required CDR
or  CDR  asymmetry  greater  than  97.5th  percentile  for  the
normal population, or a neuroretinal rim width reduced to 0.1
CDR (between 10- and 1-o’clock or 5- and 7-o’clock) with a
definite VF defect consistent with glaucoma. Category 2 was
based on advanced structural damage with unproven field
loss. This included those subjects in whom VFs could not be
determined or were unreliable, and subjects  with CDR or
CDR asymmetry greater than 99.5th percentile for the normal
population. Lastly, category 3 consisted of persons whose
optic discs could not be examined because of media opacities
and with an IOP greater than 99.5th percentile for the normal
population.
Blindness was defined as a best-corrected logMAR visual
acuity of less than 2/40 (log MAR 1.3) and/or constriction of
the VF to less than 10° from fixation in the better eye [20].
Hyperopia was defined as spherical equivalent greater than
0.50 diopters in a phakic eye [21]. Diabetes mellitus was
detected based on the current use of antidiabetic medication
and/or a random blood glucose level greater than 200 mg/dl
[22].
Thus, the primary glaucoma patients were separated into
two groups (POAG and PACG) using the following criteria.
POAG: The patients with open anterior chamber angles on
gonioscopy, typical glaucomatous cupping of optic disc and
visual field defects characteristic of glaucoma were classified
as POAG. PACG: The patients with partially or totally closed
anterior  chamber  angle  (appositional  angle  closure  or
synechiae in angle) along with damaged glaucomatous optic
disc or defective glaucomatous visual field were classified as
PACG. Subjects with any sign of secondary angle closure
(e.g.,  uveitis,  lens  related  glaucoma;  microspherophakia;
evidence of neovascularization in the angle and associated
retinal  ischemia  or  congenital  angle  anomalies)  were
excluded.  Patients  with  signs  of  intracranial  disease  that
would  cause  optic  nerve  atrophy  in  X-ray  computerized
tomography  or  magnetic  resonance  imaging  were  also
excluded.
Venous blood was collected and stored at −20 °C before
the extraction of DNA. The study protocol was approved by
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913the  ethics  committee  of  Riyadh  Military  Hospital,  and
informed consent was obtained from all study participants.
Genotyping:  The  genotypes  of  the  APOE  polymorphisms
were determined using the ApoE StripAssayTM kit (ViennaLab
Labordiagnostika GmbH, Vienna, Austria), which is based on
polymerase chain reaction (PCR) and reverse-hybridization
techniques.  The  procedure  included  three  steps:  (1)  DNA
isolation, (2) PCR amplification using biotinylated primers,
and (3) hybridization of amplification product to a test strip
containing  allele-specific  oligonucleotide  probes
immobilized as an array of parallel lines. Bound biotinylated
sequences  were  detected  using  streptavidin-alkaline
phosphatase and color substrates. To cross-check the results,
the  genotypes  of  the  APOE  polymorphisms  were  also
determined  by  PCR  and  restriction  fragment  length
polymorphism (RFLP) technique. Primers were designed on
the basis of the sequence data for APOE available in GenBank
to amplify the coding sequence of APOE. PCR was performed
using  PuRe  Taq  Ready-To-Go  PCR  Beads
(Amersham Biosciences, Piscataway, NJ) with the following
primers: forward primer: 5- GAC GCG GGC ACG GCT GTC
CAA GGA GCT GCA GGC GAC GCA GGC CCG GCT
GGA CGC GGA CAT GGA GGA-3 and reverse primer: 5 -
AGG CCA CGC TCG ACG CCC TCG CGG GCC CCG GCC
TGG TAC ACT-3.
Genomic DNA was extracted from whole blood using a
commercial  kit  (QIAmp;  Qiagen,  Hilden,  Germany).
Genomic DNA (200-300 ng) was used as a template in 25 μl
reactions. Genomic DNA was amplified for 40 cycles. Each
cycle consisted of 94 °C for 30 s, 68 °C for 10 s, and 72 °C
for  1  min.  PCR  products  obtained  were  separated  by
electrophoresis on 1.5% agarose gel in Tris-acetic acid-EDTA
(TAE)  buffer  and  visualized  by  ethidium  bromide
fluorescence. Fragments with the expected size were cut from
the  gel  and  purified  using  GFX  PCR  DNA  Gel  band
purification kit (Amersham). Purified DNA was digested with
the  CfoI  (HhaI)  enzyme  and  separated  by  agarose  gel
electrophoresis to identify the genotype. On the basis of size
and number of various fragments generated, APOE genotypes
were determined as ε2/ε2 with 144 bp and 96 bp fragments;
ε3/ε3 with 144 bp and 48 bp fragments; ε4/ ε4 with 72 bp and
48  bp  fragments;  ε2/ε3  with  144  bp,  96  bp,  and  48  bp
fragments; ε3/ ε4 with 144 bp, 72 bp, and 48 bp fragments; and
ε2/ε4 with 144 bp, 96 bp, 72 bp, and 48 bp fragments. The
prevalence of various genotypes in patients and controls was
determined.  Complete  matching  of  results  was  obtained
following both of the above mentioned procedures.
Statistical  analysis:  Frequencies  of  various  alleles  and
genotypes for each polymorphism were compared between
patients and controls and then analyzed by Fisher’s exact test
(p values less than 0.05 were considered significant). The
strength  of  the  association  of  disease  with  respect  to  a
particular antigen is expressed by an odds ratio interpreted as
relative risk (RR) according to Woolf's method as outlined by
Schallreuter et al. [23]. The RR was calculated only for those
alleles  and  genotype  that  were  increased  or  decreased  in
glaucoma patients as compared to normal Saudis.
Etiologic fraction: The etiologic fraction (EF) indicates the
hypothetical genetic component of the disease. Values greater
than 0.0 were considered significant. It was calculated for
positive association (RR>1) [24].
Preventive fraction: The preventive fraction (PF) indicates the
hypothetical protective effect of one specific antigen for the
disease. It was calculated for negative association (RR<1)
[24]. Values less than 1.0 indicated the protective effect of the
genotype/allele against the manifestation of the disease.
RESULTS
Out of 100 PG patients, 60 were diagnosed as having POAG
and 40 as having PACG. Diagnosis of POAG was based on
category 1 in nine subjects (15%) and category 2 in 51 subjects
(85%). Between category 1 and category 2, there were no
significant differences in age, IOP, or gender distribution. One
subject was blind in both eyes, and one subject had unilateral
blindness due to POAG. There were 40 subjects with PACG.
Diagnosis was based on category 1 in 10 subjects (25%),
category 2 in 28 subjects (70%), and category 3 in two subjects
(5%). Two subjects (5%) were bilaterally blind and three
(7.5%) were unilaterally blind, all due to PACG.
The frequency results of APOE alleles and genotypes in
the PG patients and the control subjects are summarized in
Table 1 through Table 6. The frequency of the ε3 allele was
significantly lower in the glaucoma patients (90%) than in the
control subjects (95.7%, p=0.034, RR=0.473, PF=0.318). In
contrast, the frequencies of the ε4 allele was significantly
higher in the glaucoma patients than in the controls (9.5%
versus 4.2%, p=0.034, RR=2.169, EF=0.329). The allele ε2
was absent in both the patient and control groups (Table 1).
Our study on various genotypes of APOE also showed
variations  in  patient  and  control  groups  (Table  2).  The
prevalence of ε3/ε3, ε3/ε4, and ε4/ε4 was 84%, 13%, and 3%
in patients and 91.5%, 8.4%, and 0% in the control group,
respectively. Though the ε3/ε3 genotype was more common
in both the test and control Saudi population, the statistical
analysis of data showed a nearly significant difference in ε3/
ε3  genotype  frequencies  between  patients  and  controls
(p=0.060,  RR=0.465,  PF=0.322).  The  difference  in  the
frequencies of the second common genotype (ε3/ε4) was not
statistically significant between the two groups (p=0.283).
Genotype ε4/ε4 was found only in 3% of patients while being
completely absent in the controls (p=0.080). The genotypes
ε2/ε2, ε2/ε3, and ε2/ε4 were absent in both the groups. These
results indicated that the ε4 allele is associated with glaucoma
and can be a risk factor while the ε3 allele may be protective
in Saudis. The frequencies of various genotypes and alleles
were  almost  similar  in  male  and  female  patients,  clearly
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distributions among populations (Table 3).
Though the distribution of APOE genotypes and alleles
was not significantly different in the two types of glaucoma
(Table 4), significant difference was found in the frequencies
of the ε4/ε4 genotype and the ε4 and ε3 alleles between the
POAG patients and controls when each glaucoma group was
compared with the controls separately. The frequencies of the
ε4/ε4 genotype and the ε4 allele were significantly higher in
POAG  patients  than  in  controls  (p=0.03  and  p=0.02,
respectively; Table 5). The frequency of the ε3 allele was
significantly  higher  in  controls  (p=0.02).  Moreover,  the
frequencies of various APOE genotypes and alleles differed
between PACG and controls, but the differences were not
statistically significant (Table 6), indicating that the ε4/ε4
genotype and ε4 allele are only significantly associated with
POAG and not with PACG in Saudis.
DISCUSSION
The results of this study showed the complete absence of the
APOE ε2 allele but a very high frequency (95.7%) of ε3. The
TABLE 1. DISTRIBUTION OF APOE ALLELE FREQUENCIES IN GLAUCOMA PATIENTS AND MATCHED CONTROLS.
Glaucoma (n=200) Control (n=260)
p value             RR EF*/PF Number Frequency (%) Number Frequency (%)
ε4 19 9.5 11 4.2 0.034 2.169 0.329*
ε3 181 90.5 249 95.7 0.034 0.473 0.318
ε2 0 0 0 0 - - -
Number of subjects=n. Values with  asterisk (last column) correspond to etiological fraction (EF) while values without asterisk
indicate  protective fraction (PF).
TABLE 2. DISTRIBUTION OF APOE GENOTYPE FREQUENCIES IN GLAUCOMA PATIENTS AND MATCHED CONTROLS.
Genotype
Glaucoma (n=100) Control (n=130)
p value             RR EF*/PF Number Frequency (%) Number Frequency (%)
ε3/ε3 84 84 119 91.5 0.06 0.465 0.322
ε3/ε4 13 13 11 8.4 0.283 1.616 0.2063*
ε4/ε4 3 3 0 0 0.08 - -
ε2/ε2 0 0 0 0 - - -
ε2/ε3 0 0 0 0 - - -
ε2/ε4 0 0 0 0 - - -
Number of subjects=n. Values with  asterisk (last column) correspond to etiological fraction (EF) while values without asterisk
indicate  protective fraction (PF).
TABLE 3. COMPARISON OF APOE GENOTYPES AND ALLELES FREQUENCIES IN MALE AND FEMALE GLAUCOMA PATIENTS.
Genotype/Allele p value Number Frequency (%) Number Frequency (%)
ε3/ε3 40 83.33 44 84.61 0.999
ε3/ε4 8 16.66 5 9.61 0.377
ε4/ε4 0 0 3 5.76 0.243
ε3 88 91.66 93 89.42 0.636
ε4 8 8.33 11 10.57 0.636
Number of subjects=n.
TABLE 4. COMPARISON OF APOE GENOTYPE AND ALLELE FREQUENCIES IN PATIENTS WITH POAG  AND PACG.
Genotype/Allele
Open angle glaucoma
            (n=60)
Angle closure glaucoma
               (n=40) p value
ε3/ε4 7 (11.66) 6 (15) 0.76
ε4/ε4 3 (5.00) 0 0.27
ε3/ε3 50 (83.33) 34 (85) 0.99
ε4 13 (10.83) 6 (7.5) 0.47
ε3 107 (89.16) 74 (92.5) 0.47
Number of subjects=n; values are indicated as n (%).
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Allele
Male (n=48)                                                          Female (n=52)frequency of ε4 (known as the thrifty allele) was 4.3% in this
Saudi population. Global studies on the APOE locus have
shown highly significant variations in the allele frequencies of
ε2 (0%–12%), ε3 (75%–90%), and ε4 (6%–20%) [25-31]. The
reason for the dissimilar findings in different populations is
far from clear and may reflect a regional difference in the
APOE genotype frequencies. The ε3 allele is the most frequent
in all the human groups, especially in populations with a long
established agricultural economy whereas the APOE ε4 allele
remains higher in populations where the economy of foraging
still  exists  or  where  the  food  supply  is/was  scarce  and
sporadically available [32].
Results  of  the  present  study  revealed  significant
differences in the frequencies of ε3 and ε4 alleles between the
glaucoma patient and the control group (Table 1). The ε3 allele
was  more  common  in  controls  while  the  ε4  allele  was
predominant  in  glaucoma  patients,  suggesting  that  the
inheritance of the ε4 allele might be a risk factor whereas ε3
may  exert  a  protective  effect  for  glaucoma  in  the  Saudi
population. Our findings are in agreement with Yilmaz et al.
[33] who reported a protective role of APOE ε3 allele in
patients  with  exfoliation  syndrome  (a  disease  closely
associated with glaucoma) in the Turkish population. The
neuroprotective effect of ε3 is evident from several earlier
studies  [34,35].  APOE  has  an  isoform-specific  effect  on
neuronal growth with ε3 stimulating neuronal elongation and
neurite  outgrowth  on  the  dorsal  root  ganglion  [34].  In
individuals  with  acute  cerebral  ischemia  such  as  an
intracerebral hemorrhage, the ε3 allele confers a much higher
rate of survival and functional recovery whereas ε4 leads to a
higher rate of disability and mortality [35].
Moreover, the results of this study clearly suggest that the
presence of ε4 has a negative impact as its presence was found
to be associated with high risk of POAG. Vickers et al. [9]
also reported an association between the ε4 allele and NTG in
the Tasmanian population. Recently, Yaun et al. [36] reported
that the ε4 allele may be a latent risk factor in developing
primary glaucoma in the Chinese population. On the other
hand, Liew et al. [37] found a weak association between
APOE ε4 and retinal microvascular degeneration.
Contrary to these findings, a decreased risk of NTG in
Chinese [13,14] and POAG in Japanese [38] has been reported
whereas some investigators reported no link between APOE
polymorphisms and glaucoma. Besides glaucoma, the APOE
ε4 allele has been identified as a genetic susceptibility factor
for a variety of neurodegenerative disorders in diverse ethnic
populations  [39-42].  The  APOE  ε4  allele  has  also  been
associated with early age-at-onset of Alzheimer’s Disease
(AD) in a dose-dependent manner [43,44]. Interestingly, a
high incidence of glaucoma in AD patients clearly suggests a
close association between these neurodegenerative disorders
[45,46]. It has been hypothesized that the cellular mechanisms
involved in the degeneration of optic nerve cells in glaucoma
are quite similar to the neurodegenerative changes in AD [9,
47,48].  The  APOE  ε4  allele  is  also  strongly  linked  with
increased  risk  of  Parkinson  disease,  schizophrenia,  and
coronary artery disease [49-55]. Possession of the ε4 allele is
also associated with a retarded recovery after traumatic head
injury [56,57].
APOE alleles modulate the biological functions of APOE
in part by altering the binding of the different lipoprotein lipid
classes [49]. Individuals carrying the ε4 allele have higher
plasma and neuronal levels of cholesterol as compared to
TABLE 5. DISTRIBUTION OF APOE GENOTYPE AND ALLELE FREQUENCIES IN PATIENTS WITH POAG AND MATCHED CONTROLS.
Genotype/Allele Open angle glaucoma (n=60) Controls (n=130) p value RR EF*/PF
ε3/ε4 7 (11.66) 11 (8.4) 0.59 1.428 0.113*
ε4/ε4 3 (5.00) 00 0.03 - -
ε3/ε3 50 (83.33) 119 (91.5) 0.13 0.462 0.255
ε4 13 (10.83) 11 (4.2) 0.02 2.75 0.034*
ε3 107 (89.16) 249 (95.7) 0.02 0.363 0.034
Number of subjects=n; values are indicated as n (%). Values with  asterisk (last column) correspond to etiological fraction (EF)
while values without asterisk indicate  protective fraction (PF).
TABLE 6. DISTRIBUTION OF APOE GENOTYPE AND ALLELE FREQUENCIES IN PATIENTS WITH PACG AND MATCHED CONTROLS.
Genotype/Allele Angle closure glaucoma (n=40) Controls (n=130) p value RR EF*/PF
ε3/ε4 6 (15) 11 (8.4) 0.236 1.909 0.167*
ε4/ε4 0 00 - - -
ε3/ε3 34 (85) 119 (91.5) 0.236 0.523 0.168
ε4 6 (7.5) 11 (4.2) 0.246 1.835 0.160*
ε3 74 (92.5) 249 (95.7) 0.246 0.544 0.161
Number of subjects=n; values are indicated as n (%). Values with  asterisk (last column) correspond to etiological fraction (EF)
while values without asterisk indicate  protective fraction (PF).
Molecular Vision 2009; 15:912-919 <http://www.molvis.org/molvis/v15/a95> © 2009 Molecular Vision
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the  ε3/ε3  genotype  in  controls  when  compared  to  the
glaucoma  patients  indicated  a  protective  effect  of  ε3/ε3
against the development of glaucoma in Saudis. On the other
hand, the ε4/ε4 genotype was only found in the patient group
with  a  complete  absence  in  the  normal  Saudi  population,
suggesting its association with POAG. The genotypes ε2/ε2,
ε2/ε3, and ε2/ε4 were absent in both the patient and control
groups.  Earlier  studies  on  APOE  polymorphisms  in  the
general population also showed the absence of genotypes
containing the ε2 allele among Saudis [58] as well as Native
Americans [59].
The results of this study suggest that APOE alleles may
influence  the  risk  of  POAG  but  has  no  effect  on  the
susceptibility of PACG. The inheritance of the ε4 allele is
associated with elevated risk of POAG but not of PACG, and
ε3  may  exert  protection  against  POAG.  However,  further
studies involving larger number of patients are warranted to
reach a definite conclusion.
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